Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 23,589 shares, a growth of 158.0% from the June 15th total of 9,143 shares. Based on an average trading volume of 19,757 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC acquired a new position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences at the end of the most recent quarter. 15.12% of the stock is currently owned by institutional investors.

Xenetic Biosciences Stock Performance

XBIO stock opened at $2.82 on Tuesday. The stock’s 50 day moving average price is $3.01 and its 200 day moving average price is $2.74. The firm has a market cap of $6.46 million, a P/E ratio of -2.35 and a beta of 2.19. Xenetic Biosciences has a 1 year low of $1.90 and a 1 year high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The company had revenue of $0.81 million for the quarter.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.